ReviewBiomolecules2026
PFAS Exposure and Metabolic Disorders: Mechanistic Insights into Lipid and Glucose Homeostasis.
Review in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Per- and polyfluoroalkyl substances (PFAS) are a class of synthetic fluorinated chemicals characterized by high environmental persistence and widespread occurrence, which have attracted increasing attention due to their potential adverse effects on human health. As the global burden of chronic diseases related to lipid and glucose dysregulation rises, identifying environmental contributors is increasingly important. Growing evidence links PFAS exposure to metabolic disorders, particularly those involving lipid and glucose metabolism. This review summarizes current findings on the mechanisms by which PFAS disrupt metabolic balance, with a focus on pathways involved in fatty acid uptake and oxidation, nuclear receptor signaling, oxidative stress, inflammation and insulin signaling. Furthermore, we highlight the convergence of molecular pathways involved in PFAS-induced lipid and glucose metabolic alterations, which may provide a mechanistic basis for understanding the development of metabolic disorders. Finally, we discuss current research limitations and future perspectives, including the potential application of computational approaches and emerging technologies to further elucidate PFAS-related metabolic effects. A comprehensive understanding of these mechanisms may help identify targets for the prevention and treatment of metabolic diseases, including obesity and type 2 diabetes, and provide regulatory policies on PFAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.